Spotlight on Imagion’s presentation at the World Imaging 2022 World Molecular Imaging Congress
Our CEO and Chairman, Bob Proulx, joined host Sonia Madigan in the Deal Room to discuss our recent WMIC 2022 poster presentation, showcasing the potential use of our MagSense® technology for prostate cancer diagnostic imaging. The data provides strong evidence that our magnetic nanoparticles have the potential to target prostate cancer tumors, which express the Prostate Specific Membrane Antigen (PSMA) with high specificity. This is the first-of-its-kind product using molecular imaging by magnetic particles to specifically identify various types of cancer.
CEO Bob Proulx stopped by the Fear and Greed podcast for a chat with host Sean Aylmer about Imagion’s pursuit of better, more precise imaging solutions to detect cancers. Bob explained how IBX’s nanoparticle technology works, talked about how the company is trying to prevent unnecessary procedures in patients, and gave an update on the advancements of our Phase I clinical trial.
In September, we presented Imagion’s value proposition to an audience of investors and finance enthusiasts at the Switzer Conference. Our CEO, Bob Proulx talked through a recent investor presentation regarding the company's mission and direction, and also participated in a live Q&A session with host Peter Switzer.
In September, we joined a panel of experts from nanoComposix | Fortis Life Sciences to discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery in a webinar series hosted by Drug Discovery News. Request access to the recorded webinar below.
.png?upscale=true&width=1200&upscale=true&name=IB%20in%20the%20News%20email%20header%20(1).png)
